Cristina Peixoto

Dr. Cristina Peixoto


Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2000 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
PMPedro M Matias
Pedro M Matias
PDPeter Donner
Peter Donner
RCRicardo Coelho
Ricardo Coelho
MTMonica Thomaz
Monica Thomaz
CPCristina Peixoto
Cristina Peixoto
MCMaria Arménia Carrondo
Maria Arménia Carrondo
The crystal structures of the human androgen receptor (hAR) and human progesterone receptor ligand-binding domains in complex with the same ligand metribolone (R1881) have been determined. Both three-dimensional structures show the typical nuclear receptor fold. The change of two residues in the ligand-binding pocket between the human progesterone receptor and hAR is most likely the source for the specificity of R1881 to the hAR. The structural implications of the 14 known mutations in the ligand-binding pocket of the hAR ligand-binding domains associated with either prostate cancer or the partial or complete androgen receptor insensitivity syndrome were analyzed. The effects of most of these mutants could be explained on the basis of the crystal structure.

1 July 2011 in Journal of Invertebrate Pathology
Verified
Journal Article
Closed access
TVTiago Vicente
Tiago Vicente
ARAntónio Roldão
António Roldão
CPCristina Peixoto
Cristina Peixoto
MOManuel D. Ortigueira
Manuel D. Ortigueira
PAPaula M Alves
Paula M Alves

13 February 2015 in Biotechnology and Bioengineering
Verified
Journal Article
Closed access
PDF file
PNPiergiuseppe Nestola
Piergiuseppe Nestola
CPCristina Peixoto
Cristina Peixoto
RSRicardo Silva
Ricardo Silva
PAPaula M Alves
Paula M Alves
José P. B. MotaJosé P. B. Mota
José P. B. Mota
MOManuel D. Ortigueira
Manuel D. Ortigueira

27 November 2019 in Expert Opinion on Biological Therapy
Verified
Journal Article
Open access
MMMafalda G. Moleirinho
Mafalda G. Moleirinho
RSRicardo Silva
Ricardo Silva
PAPaula M Alves
Paula M Alves
MCManuel J. T. Carrondo
Manuel J. T. Carrondo
CPCristina Peixoto
Cristina Peixoto
Introduction: The development of novel complex biotherapeutics led to new challenges in biopharmaceutical industry. The potential of these particles has been demonstrated by the approval of several products, in the different fields of gene therapy, oncolytic therapy, and tumor vaccines. However, their manufacturing still presents challenges related to the high dosages and purity required. Areas covered: The main challenges that biopharmaceutical industry faces today and the most recent developments in the manufacturing of different biotherapeutic particles are reported here. Several unit operations and downstream trains to purify virus, virus-like particles and extracellular vesicles are described. Innovations on the different purification steps are also highlighted with an eye on the implementation of continuous and integrated processes. Expert opinion: Manufacturing platforms that consist of a low number of unit operations, with higher-yielding processes and reduced costs will be highly appreciated by the industry. The pipeline of complex therapeutic particles is expanding and there is a clear need for advanced tools and manufacturing capacity. The use of single-use technologies, as well as continuous integrated operations, are gaining ground in the biopharmaceutical industry and should be supported by more accurate and faster analytical methods.

16 January 2007 in Acta Crystallographica Section D Structural Biology
Verified
Journal Article
Open access
PDF file
IBIsabel Bento
Isabel Bento
CPCristina Peixoto
Cristina Peixoto
VZVjacheslav N. Zaitsev
Vjacheslav N. Zaitsev
PLPeter F. Lindley
Peter F. Lindley
The three-dimensional molecular structure of human serum ceruloplasmin has been reinvestigated using X-ray synchrotron data collected at 100 K from a crystal frozen to liquid-nitrogen temperature. The resulting model, with an increase in resolution from 3.1 to 2.8 A, gives an overall improvement of the molecular structure, in particular the side chains. In addition, it enables the clear definition of previously unidentified Ca2+-binding and Na+-binding sites. The Ca2+ cation is located in domain 1 in a configuration very similar to that found in the activated bovine factor Va. The Na+ sites appear to play a structural role in providing rigidity to the three protuberances on the top surface of the molecule. These features probably help to steer substrates towards the mononuclear copper sites prior to their oxidation and to restrict the size of the approaching substrate. The trinuclear copper centre appears to differ from the room-temperature structure in that a dioxygen moiety is bound in a similar way to that found in the endospore coat protein CotA from Bacillus subtilis.

1 January 2007 in Journal of Biotechnology
Verified
Journal Article
Closed access
CPCristina Peixoto
Cristina Peixoto
MSMarcos Sousa
Marcos Sousa
ASA.C. Silva
A.C. Silva
MOManuel D. Ortigueira
Manuel D. Ortigueira
PAPaula M Alves
Paula M Alves